U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07046156) titled 'Treatment of Overactive Bladder With Anticholinergic Agents' on June 23.
Brief Summary: This study aims to evaluate the efficacy and adverse effect incidence of three different anticholinergics (oxybutinin, propiverine, and tolterodine) that are used in children with overactive bladder.
Study Start Date: Sept. 01, 2022
Study Type: OBSERVATIONAL
Condition:
Overactive Bladder
Intervention:
DRUG: Oxybutynin Cl
Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder
DRUG: propiverine
Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder
DRUG: Tolterodine
Tolterodin...